We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.00 | 33.10 | 34.90 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/3/2017 07:28 | Interesting news this morning | mirabeau | |
17/3/2017 07:12 | Nice r n s watch it grow | jammytass | |
01/10/2016 09:33 | This is not making any recovery and serves as a reminder of the risks in this type of investment. Probably better to invest via a Fund to spread risk. | 888icb | |
23/6/2016 04:08 | Circassia Pharmaceuticals extended Tuesday’s rebound 23rd June 2016 Circassia Pharmaceuticals, which on Monday tumbled more than 60 per cent after its cat allergy trial collapsed, extended Tuesday’s rebound, climbing 8.7 per cent, or 8.5p to 105.5p. | dice1950 | |
21/6/2016 19:53 | Peel Hunt said: Circassia uncertainty overhang medium-term unless a strategic bid emerges. 21st June 2016 | dice1950 | |
21/6/2016 08:20 | RBC Capital Markets, Peel Hunt Circassia slashed after poor test results - … - #CIR | dice1950 | |
21/6/2016 08:18 | Tempus in today's Times says its a buy. When Circassia came to the market in 2014 at 310p a share, it was seen as the owner of a promising but unproven treatment for allergies, including hay fever. En route the company paid £239 million for a couple of companies making treatments for asthma and pulmonary disease, raising fresh funds at 288p a share. The first widescale trials of that allergy treatment for people allergic to cats have been an unmitigated disaster. Put simply, sufferers given the treatment did well but so did those given a placebo. This is frankly baffling. Circassia is giving up trials of the same treatment for sufferers of hay fever and those allergic to ragweed, though two others are sufficiently well advanced that there is no point in abandoning them. The conclusion of these may give an idea why the feline trials went so badly and whether the treatment has any value whatsoever. This leaves the company with those asthma products, several of which are on the market. If the study was baffling, the market’s response was equally so. Circassia shares lost two thirds of their value, falling 179¼p to 91p. This gives it a market capitalisation of £257 million. Tot up the cost of those acquisitions and the cash in the bank and you get to £379 million. This suggests that the fall in the price is wildly overdone, assuming those businesses bought have the value ascribed to them, with the original allergy treatment assigned no value whatsoever. Any biotech company is always going to be speculative, but this looks a good gamble. MY ADVICE Buy WHY Risky, but the share price fall looks overdone | paleje | |
21/6/2016 07:37 | Dead cat bounce....... | muffster | |
20/6/2016 20:40 | Numis said: Circassia Pharmaceuticals has collapsed 64% 20th June 2016 | dice1950 | |
20/6/2016 18:38 | Can't see this bouncing till the low 50's | investment dave | |
20/6/2016 17:01 | Oh dear looks like 40p is on the cards cash at the bank valuation. | catswhiskas | |
20/6/2016 16:33 | Also Woody sells he BT stake why? | montyhedge | |
20/6/2016 16:32 | Never admit that you were wrong or the game's all over hxxps://woodfordfund | mammyoko | |
20/6/2016 16:16 | https://woodfordfund | kooba | |
20/6/2016 13:23 | will this bounce? | 1toad | |
20/6/2016 09:53 | Oh dear, Woody's lost another £100m of other people's money | mammyoko | |
20/6/2016 09:20 | bleaurghhhhhhhhhhhhh | ch4p_85 | |
20/6/2016 07:33 | dead cat bounce? | pugg1ey | |
20/6/2016 07:20 | This cat's dead. There are a whole lot of other fat cats in the portfolio...stuck high up in the tree. | liquidkid | |
20/6/2016 06:55 | Miaow! :-/ | cottoner | |
20/6/2016 06:51 | Not looking forward to them now...... | deltrotter | |
25/5/2016 15:02 | As expected and to schedule, "...we are looking forward to receiving the results from our cat allergy pivotal phase III study in the coming weeks." Pivotal indeed. | elgordo | |
19/1/2016 14:16 | To be fair, it's hard to discern anything from that other than he doesn't like it. | hutch_pod | |
19/1/2016 13:44 | I see Evil Knievel has put the boot in: Poor old Neil Woodford. The investing public have really got it in for him now. He’s an example of the longstanding observation that first they put you on a pedestal and then they knock you down. His investment in Circassia (CIR) seems to be another example. Anyway, it seems that there is nothing in this company whatsoever. At 315p it is capitalised at £900m as against ntav of £169m at 30th June 2015. This figure is falling since losses are running at around £50m p.a.! There is circa £200m of cash. Which is a lot for a deadbeat proposition. However, the end result is the same. | wiseacre |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions